PrintyMed PrintyMed—Biomimetic spider silk membranes for Organ-on-a-Chip solutions
- Coordinator
- Printymed, Latvia
- Runs
- 1 June 2026 to 30 November 2027
- Status
- Running
- EU funding
- €500k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- Coordination and Support Action
- Grant agreement
- 101310754
What the project is doing
In the project's own words, from its summary on CORDIS.
Drug development remains slow, risky, and inefficient: it takes 10–15 years, costs €1–2B per approved drug, and over 90% of candidates fail, largely due to inadequate preclinical models. As innovation slows and costs rise, regulators in the EU and US increasingly mandate human-relevant, non-animal methods. Organ-on-Chip (OoC) systems offer physiological relevance, yet their adoption is restricted by one critical bottleneck: the membrane.
Current membranes absorb drugs, lack physiological elasticity, require unstable animal-derived coatings, and degrade under flow, limiting OoC performance. PrintyMed addresses this limitation with a proprietary biomimetic spider silk. Engineered to replicate natural spinning, we combine recombinant mini-spidroins optimized for microbial expression with controlled molecular self-assembly and a patented PEG-based tuning step for precise control of mechanics and surface chemistry.
In this project, we will complete the engineering optimisation and validation of our ultrathin, elastic, permeable, optically clear, biocompatible spider-silk membrane and establish a reproducible, scalable, water-based manufacturing process. We will benchmark mechanical, chemical, and biological performance, and integrate the membrane into a state-of-the-art Gut-on-Chip to reach TRL 6. We will validate intrinsic cell adhesion, growth, TEER stability, and barrier function without animal-derived coatings, confirming the membrane as ready for OoC deployment.
We will prepare a draft patent application and outline the regulatory and industrial scale-up roadmap. Newly generated IP on OoC-specific membrane architectures and surface chemistries will position PrintyMed as the first specialised supplier of medical-grade, tunable, biomimetic membranes in the rapidly growing market. By unlocking the missing materials layer for next-generation OoC systems, PrintyMed enables more predictive drug testing, fewer clinical failures, and faster therapeutic development.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Printymed | Jelgavas Novads | Latvia | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI